Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis
Table 1
(a) Proliferative lupus nephritis (PLN) background information on based on electronic medical record chart review. Medians presented with 25% and 75% values in parentheses for continuous data because they were not normally distributed. Some percentages are accompanied by in parentheses. Prednisone dose was <10 mg/d. Other immunosuppression was discontinued at least 6 months before confirmatory kidney biopsy. Not all patients had information available for each laboratory measurement. SLE, systemic lupus erythematosus; PLN, progressive lupus nephritis; LN, lupus nephritis; CNS, central nervous system; RBC, red blood cell; dsDNA, double-stranded DNA; SM, smooth muscle; RNP, ribonucleoprotein; CRP, C-reactive protein; NIH, National Institutes of Health.
Average age (range)
36 years old (18–60)
Race
Caucasian
15%
African American
60%
Other
25%
Gender
Female
65%
History of HTN
83 (19/23)
History of DM
0 (0/23)
Arthralgia
70 (16/23)
Dermatologic
48 (11/23)
Hematologic
53 (12/23)
Cardiac involvement
35 (8/23)
CNS involvement
9 (2/23)
Lung involvement
35 (8/23)
Liver involvement
9 (2/23)
Hematuria (>3 RBC phf)
100 (23/23)
Proteinuria (>300 mg)
100 (23/23)
Nephrotic range proteinuria (>3.5 gm)
35 (8/23)
Proteinuria Quantification (average in gm)
2.36 (0.380–4.61)
Serum Creatinine (average mg/dl)
1.13 (0.6–2.4)
ANA (% positive)
96 (22/23)
dsDNA antibody (% positive)
82 (18/22)
Average (titer)
1 : 320
Average (U/mL peak; )
189 (130–228)
dsDNA antibody OR ANA (% positive)
100 (23/23)
ANCA (% positive)
0 (0/3)
Anti-phospholipid antibody (% positive)
38 (8/23)
Anti-SM antibody (% positive)
38 (6/16)
Anti-RNP antibody (% positive)
50 (8/16)
CRP
(Average mg/dL)
2.1 (0.1–6.6)
(% >0.8 mg/dL)
79 (11/14)
Biopsy (%)
WHO Class III
22 (5/23)
WHO Class IV
78 (18/23)
WHO Class IV + V
35 (8/23)
Crescent Formation
23 (6/23)
Median NIH activity index
8
Median NIH chronicity index
3
Median SLE disease activity index
16
Immunosuppression before biopsy (%)
Prednisone
22 (5/23)
Hydroxychloroquine
39 (9/23)
Other (cyclophosphamide, mycophenolate mofetil, rituximab)
9 (2/23)
(b) Systemic lupus erythematosus (SLE) without lupus nephritis (LN) disease control background information on based on ICD-9 codes provided by the Department of Defense Serum Repository (DoDSR). Laboratory data were not available for these disease control patients.
